A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma

Patrick Y. Wen, David A. Reardon, Terri S. Armstrong, Surasak Phuphanich, Robert D. Aiken, Joseph C. Landolfi, William T. Curry, Jay Jiguang Zhu, Michael Glantz, David M. Peereboom, James M. Markert, Renato LaRocca, Donald M. O'Rourke, Karen Fink, Lyndon Kim, Michael Gruber, Glenn J. Lesser, Edward Pan, Santosh Kesari, Alona MuzikanskyClemencia Pinilla, Radleigh G. Santos, John S. Yu

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Purpose: To evaluate the results of the randomized, double-blind, placebo-controlled phase II clinical trial of ICT-107 in patients with newly diagnosed glioblastoma. Patients and Methods: We conducted a double-blinded randomized phase II trial of ICT-107 in newly diagnosed patients with glioblastoma (GBM) and tested efficacy, safety, quality of life (QoL), and immune response. HLA-A1þ and/or -A2þ–resected patients with residual tumor ≤1 cm3 received radiotherapy and concurrent temozolomide. Following completion of radiotherapy, 124 patients, randomized 2:1, received ICT-107 [autologous dendritic cells (DC) pulsed with six synthetic peptide epitopes targeting GBM tumor/stem cell–associated antigens MAGE-1, HER-2, AIM-2, TRP-2, gp100, and IL13Ra2] or matching control (unpulsed DC). Patients received induction ICT-107 or control weekly x 4 followed by 12 months of adjuvant temozolomide. Maintenance vaccinations occurred at 1, 3, and 6 months and every 6 months thereafter. Results: ICT-107 was well tolerated, with no difference in adverse events between the treatment and control groups. The primary endpoint, median overall survival (OS), favored ICT-107 by 2.0 months in the intent-to-treat (ITT) population but was not statistically significant. Progression-free survival (PFS) in the ITT population was significantly increased in the ICT-107 cohort by 2.2 months (P ¼ 0.011). The frequency of HLA-A2 primary tumor antigen expression was higher than that for HLA-A1 patients, and HLA-A2 patients had higher immune response (via Elispot). HLA-A2 patients achieved a meaningful therapeutic benefit with ICT-107, in both the MGMT methylated and unmethylated prespecified subgroups, whereas only HLA-A1 methylated patients had an OS benefit. Conclusions: PFS was significantly improved in ICT-107–treated patients with maintenance of QoL. Patients in the HLA-A2 subgroup showed increased ICT-107 activity clinically and immunologically.

Original languageEnglish (US)
Pages (from-to)5799-5807
Number of pages9
JournalClinical Cancer Research
Volume25
Issue number19
DOIs
StatePublished - Oct 1 2019

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma'. Together they form a unique fingerprint.

  • Cite this

    Wen, P. Y., Reardon, D. A., Armstrong, T. S., Phuphanich, S., Aiken, R. D., Landolfi, J. C., Curry, W. T., Zhu, J. J., Glantz, M., Peereboom, D. M., Markert, J. M., LaRocca, R., O'Rourke, D. M., Fink, K., Kim, L., Gruber, M., Lesser, G. J., Pan, E., Kesari, S., ... Yu, J. S. (2019). A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clinical Cancer Research, 25(19), 5799-5807. https://doi.org/10.1158/1078-0432.CCR-19-0261